Compare Abeona Therapeutics Inc (ABEO) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs UiPath Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while UiPath Inc trades at $11.42 (market cap $6.04B). The key difference: UiPath Inc is far larger — about 16.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PATH | |
|---|---|---|
Market Cap | $373.32M | $6.04B |
Sector | Health | Technology |
52-Week High | $7.23 | $19.29 |
52-Week Low | $4.17 | $9.38 |
Enterprise Value | $228.22M | $4.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
UiPath (PATH) trades at $11.65, down 0.51% on the day, with a bullish technical signal driven by moving averages. The company shows improving fundamentals with revenue growth from $1.43B in 2025 to a projected $1.7B in 2026 and a shift to profitability. Recent news highlights expansion in agentic AI and enterprise automation, though the stock faces competitive and execution risks.
The outlook is cautiously optimistic with a consensus price target of $13.33 suggesting 14% upside. Key opportunities include strong revenue growth and margin expansion, while risks involve intense competition and the need to sustain AI-driven adoption. Analyst sentiment is mixed with 25% buy ratings amid ongoing transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
